[
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-0",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "NSCLC: Stage at Diagnosis",
    "content": "<!-- Page 1 -->\n\nDIAGNOSIS\n∿\n\n---\n\n<!-- Page 2 -->\n\n\n\n# NSCLC: Stage at Diagnosis\n\n(SCLC)\n\n*   Stage I: 10%\n*   Stage II: 20%\n*   Stage IIIA: 15%\n*   Stage IIIB: 15%\n*   Stage IV: 40%\n    *   (NO Surgery)\n\nEttinger et al. Oncology. 1996; 10:81-111.\n\n---\n\n<!-- Page 3 -->\n\n\n\n# 5 Year Survival Rates – By Stage\n\n*   Non-Small Cell Lung Cancer\n    *   IA 58-73%\n    *   IB 43-58%\n    *   IIA 36-46%\n    *   IIB 25-36%\n    *   IIIA 19-24%\n    *   IIIB 7-9%\n    *   IV 2-13%\n*   Small Cell Lung Cancer\n    *   Limited 18-38%\n    *   Extensive 1%\n\n---\n\n<!-- Page 4 -->\n\n\n\n# Objectives of evaluation\n\nThe main objectives of the diagnostic evaluation and clinical staging are\n* adequate tissue to establish the HPE diagnosis and,\n* molecular characterization of the tumor,\n* extent of disease\n\nThese goals should be accomplished in the safest, least invasive, and most cost-effective manner possible.\n\n---\n\n<!-- Page 5 -->\n\nIMAGING EVALUATION\n\n---\n\n<!-- Page 6 -->\n\n\n\n# Lung cancer : Investigations\n\n*   I. CXR\n*   CT CHEST (precise location)\n*   CYTOLOGY (Sputum, Pleural fluid)\n*   GOLD STD TEST: ? Biopsy\n    *   HPE\n    *   IHC\n    *   Molecular testing (Driver mutations, PDL1 status)\n*   MRI\n*   PET\n*   Bonescan\n\nDr. Bharath Katti MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 7 -->\n\n\n\n# I. CHEST XRAY\n\n? malignancy\n\n1.  Solitary Pul nodule\n2.  Mass [Spiculated]\n3.  Collapse\n4.  Plef\n5.  mediastinal LN↑\n6.  Pericardral effusion\n7.  ↑ diaphragm elevation\n8.  Rib #\n\nOthers :\n-   Diffuse interstitial disease Lymphangitis carcinomatosis\n-   Consolidation ✓\n-   Cavity\n\n---\n\n<!-- Page 8 -->\n\n\n\n## II. CT chest\n\nCT - key features of the primary tumor (size, presence of satellite nodules, associated atelectasis, and invasion of adjacent structures);\n\nRegional LN involvement can also be evaluated on chest CT. \\* Staging\n\nLymph nodes are deemed to be pathologically enlarged when they measure greater than 1 cm in short-axis diameter on transverse images\n\nThe likelihood of metastatic involvement increases with the degree of lymph node enlargement: 62% of lymph nodes measuring 10 to 15 mm are malignant versus 90% of nodes measuring >15 mm.\n\nIn meta analysis About 20% of nodes deemed to be benign on chest CT were malignant\nand 40% of nodes deemed abnormal on chest CT were benign\n\n---\n\n<!-- Page 9 -->\n\nChest CT can also demonstrate findings - metastatic disease.\nCT helps to delineate pleural disease;\nBony involvement of the thoracic cage may be seen.\nAdrenal lesions can be identified\n\n---\n\n<!-- Page 10 -->\n\nIV contrast : CECT\n1) differentiate the hilar and mediastinal lymph nodes from vascular structures\n2) also helps to characterize hepatic and adrenal lesions.\n3) neovascularity\n\n---\n\n<!-- Page 11 -->\n\n\n\n### III Sputum cytology\n\nLeast invasive way of achieving a **histologic** diagnosis.\n\nHowever, it is also the **least accurate** and least useful for therapeutic analysis. For these reasons, it has largely been replaced by other methods and is generally of **historic interest only**.\n\nmale patients predominating. Sensitivity of sputum cytology is 60%, and it increases with the number of samples examined. It is more for the central lesion compared with the peripheral lesion, and for squamous cell carcinoma compared with adenocarcinoma. Use of both sputum and BAL cytology increases the detection rate of lung cancer. Need for careful evaluation is patients with a sputum cytodiagnosis of\n\nORIGINAL ARTICLE\n**Sputum cytology in suspected cases of carcinoma of lung (Sputum cytology a poor man's bronchoscopy!)**\n\nAmmanagi, A. S.; Dombale, V. D.; Miskin, A. T.; Dandagi, G. L.; Sangolli, S. S.\nAuthor Information\n\nLung India 29(1):p 19-23, Jan-Mar 2012. | DOI: 10.4103/0970-2113.92356\n\n---\n\n<!-- Page 12 -->\n\n\n\n# Thoracentesis\n\nMost effusions in _lung cancer_ are _malignant_.\n\nPositive pleural fluid cytology establishes the diagnosis and also establishes stage IV disease.\n\nPleural fluid cytology sensitivity for malignancy overall is approximately 60% to 72% when a volume of at least 50 mL is sent; diagnostic yield does not appear to increase with larger volume of fluid analyzed.\n\nIf the initial thoracentesis is negative, a second thoracentesis should be performed, as it can increase the diagnostic yield by an additional 27%; additional samples add little to the diagnostic yield.\n\nSensitivity of pleural fluid cytology can be as high as 72% when at least two separate specimens are sent.\n\n---\n\n<!-- Page 13 -->\n\nWhen pleural disease is present and thoracentesis is negative:\nClosed pleural biopsy using an Abrams needle (7% to 27%).\n\\*image-guided pleural biopsy\\*: with a sensitivity of 84%.\n\\*Thoracoscopy\\* has a reported sensitivity of 80% to 99% in the diagnosis of malignant pleural disease.\nwhen there is CT evidence of pleural thickening or nodules, the diagnostic yield of image-guided percutaneous biopsy is similar to thoracoscopy.\n\n---\n\n<!-- Page 14 -->\n\n**PET-CT** : metastasis\n\nFGD-PET PET-ve ❌ Not malignancy\n\nmore sensitive and specific than CT in regional lymph node assessment disclose unsuspected metastatic disease in 6% to 37% of cases.\n\nLiver metastases, adrenal metastases, and bone metastases can be diagnosed with good accuracy.\n\n---\n\n<!-- Page 15 -->\n\n\n\n# MRI\n\nMRI scanning is the test of choice when assessing for intracranial metastatic disease.\n\nMRI is also the test of choice for:\n*   extent of chest wall invasion,\n*   diaphragmatic involvement,\n*   superior sulcus tumors,\n*   brachial plexus invasion,\n*   invasion of the spine (T4 disease).\n\n---\n\n<!-- Page 16 -->\n\n\n\n# ESTABLISHING THE TISSUE DIAGNOSIS\n\n*   ?? Biopsy\n    *   CT guided\n    *   Br. Biopsy\n    *   Thoracoscopy\n    *   SLB\n\n---\n\n<!-- Page 17 -->\n\n\n\n# HISTOLOGIC SAMPLING OF THE PRIMARY TUMOR\nBetter Yield $\\bar{c}$ central tumor.\n\n| TUMOR CHARACTER                       | PROCEDURE                         | SENSITIVITY |\n| :------------------------------------ | :-------------------------------- | :---------- |\n| DIRECTLY VISUALIZED ENDOBRONCHIAL TUMOR Biopsy (drawing of bronchus with tumor) | BRONCHOSCOPY WITH FORCEPS BIOPSY | \\* 75% \\*   |\n|                                       | BRONCHOSCOPIC WASH                | 47%         |\n|                                       | ENDOBRONCHIAL BRUSH               | 61%         |\n\n---\n\n<!-- Page 18 -->",
    "wordCount": 973,
    "index": 0,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-1",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "PERIPHERAL LESIONS",
    "content": "# PERIPHERAL LESIONS\n\nCT guided Biopsy",
    "wordCount": 6,
    "index": 1,
    "subTopicId": "1766794361883-f2tuqhh08"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-2",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "| | |",
    "content": "| | |\n| :-------------------------------- | :--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n|\n| **Category** | **Description** |\n|---|---|\n| **Title** | PERIPHERAL LESIONS |\n| **Table: Biopsy Methods and Success Rates** | |\n| TRANBRONCHIAL BIOPSY | 57% (1 SAMPLE: 45%; $\\uparrow$ PTx Multiple SAMPLE: 70%) (6 Sample) |\n| BRONCHOALVEOLAR WASH | 43% |\n| TRANSBRONCHIAL NEEDLE ASPIRATION | 65% |\n| TRANSTHORACIC NEEDLE ASPIRATION | |\n| CT GUIDED | 92% |\n| FLUOROSCOPY GUIDED | 88% |\n| **Additional Notes** | |\n| | - R-EBUS permits direct realtime ultrasound imaging of target lesions; early studies suggested |\n| | - R-EBUS can increase the overall sensitivity of bronchoscopic biopsy of peripheral lesions up to 73%. |\n| | - EMN increases the diagnostic yield of bronchoscopic biopsy of peripheral lesions from 57% overall to 70%. |",
    "wordCount": 136,
    "index": 2,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-3",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 19 -->\n\nWhen all techniques are utilized, reported yield of\nbronchoscopic sampling of endobronchial lesions can be\nas high as 91% to 96%.\nThe utility of bronchoscopic sampling in patients with\nperipheral primary tumor is much lower.\n\n---\n\n<!-- Page 20 -->\n\nTrans bronchial needle biopsy\n\nTTNB is recommended as the first line for biopsy of peripheral lung lesions in intermediate to high lung cancer likelihood patients when\n(1) the lesion is peripheral;\n(2) the lesion is less than 3 cm in size;vvvnnn\nn (3) there is no CT/PET evidence of mediastinal lymph node or extrathoracic metastasis; and/or (4) the patient is a poor surgical candidate.\n\nDR. BHARATH KATHI MD DNB FIP FACR EDARM\n\n---\n\n<!-- Page 21 -->",
    "wordCount": 122,
    "index": 3,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-4",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "SLB",
    "content": "# SLB\n\nVideo-assisted thoracoscopic surgery (**VATS**) wedge resection followed by definitive anatomic resection (e.g., lobectomy) as indicated is the **gold standard** for **peripheral lung biopsy** with the **highest sensitivity and specificity**. (More risky) invasive\n\nIn patients who have an acceptable surgical risk profile, a peripheral lesion **less than 3 cm**, and **no CT/PET evidence of metastatic disease** (lymph node or extrathoracic), **definitive VATS resection is preferred**, as it provides both **diagnosis and cure in one procedure**.\n\nOtherwise, despite overall lower yield, `bronchoscopic sampling` has become the preferred biopsy method in centers where `advanced bronchoscopy` technologies, including `R-EBUS` and `EMN`, are available\n\n---\n\n<!-- Page 22 -->\n\n\n\n# MEDIASTINAL STAGING\n\n*   Nearly a quarter of patients with lung cancer have locally advanced disease with mediastinal involvement (N2 or N3) at the time of presentation.\n*   Mediastinal staging is crucial in determining the stage of disease and candidacy for surgical resection once metastatic disease has been ruled out, as 29% to 66% of noncurative surgeries for lung cancer can be avoided with adequate mediastinal staging\n*   Tissue confirmation of mediastinal nodal metastasis becomes unnecessary only in the following situations: (1) where distant metastatic disease has already been confirmed; (2) when the patient is not a candidate for any treatment; (3) in a peripheral lesion, less than 3 cm in size, with no radiographic evidence of lymph node metastasis\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 23 -->\n\nPatients with NSCLC -clinical staging of the mediastinum based on the radiographic findings\n\n| Group | Description                                                                                                                            |\n| :---- | :------------------------------------------------------------------------------------------------------------------------------------- |\n| A     | Mediastinal infiltration: tumor invasion such that normal anatomic boundaries cannot be distinguished                                  |\n| B     | Enlarged discrete mediastinal lymph nodes: lymph nodes measuring $\\ge$1 cm in short-axis diameter on transverse CT scan                |\n| C     | Clinical stage II or central stage I tumor: normal-sized mediastinal lymph nodes but enlarged N1 nodes or central tumor                |\n| D     | Peripheral clinical stage I tumor: normal mediastinal and hilar nodes with a peripheral tumor                                          |\n\n---\n\n<!-- Page 24 -->\n\nDr. Sharath Katte\n\nFigure 112-2 Example of radiographic group A disease mediastinal infiltration with loss of normal anatomic boundaries.\n\n---\n\n<!-- Page 25 -->\n\nFigure 112-3 Example of radiographic Group B disease: discrete mediastinal (4R) nodal enlargement\n\n---\n\n<!-- Page 26 -->\n\n\n\n# Mediastinal staging\n\nMediastinal staging procedures include\n*   Transthoracic needle aspiration (TTNA),\n*   Transbronchial needle aspiration (TBNA) with or without endobronchial ultrasound (EBUS),\n*   Endoscopic ultrasound (EUS) needle aspiration,\n*   Cervical mediastinoscopy,\n*   Anterior mediastinoscopy,\n*   Thoracoscopy.\n\nSelection of *appropriate procedure* is made based upon *nodal station, pretest probability* of disease, and medical appropriateness for surgical resection.\nThe diagnostic yield of *each procedure* should also be taken into account.\n\n---\n\n<!-- Page 27 -->\n\n\n\n# Regional lymph nodes\n\n\n\n## Supraclavicular zone\n*   1 Low cervical, supraclavicular, and sternal notch nodes\n\n\n\n## SUPERIOR MEDIASTINAL NODES\n\n\n### Upper zone\n*   2R Upper Paratracheal (right)\n*   2L Upper Paratracheal (left)\n*   3a Prevascular\n*   3p Retrotracheal\n*   4R Lower Paratracheal (right)\n*   4L Lower Paratracheal (left)\n\n\n\n## AORTIC NODES\n\n\n### AP zone\n*   5 Subaortic\n*   6 Para-aortic (ascending aorta or phrenic)\n\n\n\n## INFERIOR MEDIASTINAL NODES\n\n\n### Subcarinal zone\n*   7 Subcarinal\n\n\n### Lower zone\n*   8 Paraesophageal (below carina)\n*   9 Pulmonary ligament\n\n\n\n## N1 NODES\n\n\n### Hilar/Interlobar zone\n*   10 Hilar\n*   11 Interlobar\n\n\n### Peripheral zone\n*   12 Lobar\n*   13 Segmental\n*   14 Subsegmental\n\nAdolfo San Juan, MD 2009\n\n---\n\n<!-- Page 28 -->\n\n\n\n# Mediastinal Staging\n\n| Procedure | Lymph Node Stations | Sensitivity (%) |\n|---|---|---|\n| TBNA | 4, 7, and 10 | 78 |\n| EBUS-TBNA | 2, 4, 7, and 10 | 88–93 |\n| EUS-FNA | 5, 7–9 | 83, overall<br>90, enlarged nodes<br>58, normal-sized nodes |\n| CT-guided TTNA | 3a, 5, 6 | 92 |\n| Mediastinoscopy | 1, 2R, 2L, 3, 4R, 4L, anterior subcarinal (7) | 81 |\n| Thoracoscopy | 4, 7–10 | 99 |\n\n---\n\n<!-- Page 29 -->\n\n\n\n# TNM STAGING FOR LUNG CANCER {8TH EDITION} NSCLC\n\n*Annotations:*\n*   **T**: Tumor\n*   **N**: Node\n*   **M**: Metastasis\n*   SCLC (circled)\n\n---\n\n<!-- Page 30 -->\n\nT1 and T2 further divided into 1-cm increments.\nCentral tumors involving a main bronchus are considered T2, regardless of distance from, but without involvement of, the main carina.\nInvolvement of the diaphragm has been reclassified as T4. The classification of additional tumor nodules was maintained from the previous classification. The presence of a satellite nodule in the tumor-bearing lobe defines T3, whereas an additional nodule in a different lobe of the ipsilateral lung defines T4.\nThe N category has remained unchanged in the last two iterations of the staging system and is determined by the location of the involved nodes (relative to the primary tumor).\nThe M category has been further divided into M1a, b, and c, as prognosis was found to worsen increasingly from a to c.\n\n---\n\n<!-- Page 31 -->\n\nT1-T4\n\n*   **T1**: **Tumor ≤ 3 cm** surrounded by **visceral pleura** not involving main bronchus\n    *   T1a : <1 cm\n    *   T1b : 1-2cm\n    *   T1c : >2cm to ≤ 3\n\nT2 : tumour **> 3 cm to 5 cm** or\n- any tumor that invades **visceral pleura** or main **bronchus** or\n  **atelectasis up to hilum**\n✓ T2a : >3cm to 4cm\n✓ T2b : > 4cm to 5cm\n\n---\n\n<!-- Page 32 -->\n\n\n\n## T3\n\nTumor >5 cm but ≤7 cm or Tumor that invades\n<u>chest wall</u> (including superior <u>sulcus tumors</u>), <u>phrenic nerve</u>, <u>parietal pericardium</u>; or <u>satellite nodule(s) in the same lobe as the primary</u>\n\n\n\n## T4\n\n*   ESOPHAGUS\n*   GREAT VESSELS\n*   R/C LARYNGEAL NERVE\n*   SPINE\n\nTumor >7 cm or tumor that invades <u>trachea</u>, <u>carina</u>, <u>diaphragm</u>, <u>mediastinum</u> (<u>heart</u>, <u>great vessels</u>, <u>recurrent laryngeal nerve</u>, <u>esophagus</u>,) <u>vertebral body</u>, <u>separate tumor nodule(s) in another lobe same side</u>.\n\n---\n\n<!-- Page 33 -->\n\nNodal Staging\n14\n\n**Supraclavicular zone**\n*   1 Low cervical, supraclavicular, and sternal notch nodes\n\n**SUPERIOR MEDIASTINAL NODES**\n**Upper zone**\n*   2R Upper Paratracheal (right)\n*   2L Upper Paratracheal (left)\n*   3a Prevascular\n*   3p Retrotracheal\n*   4R Lower Paratracheal (right)\n*   4L Lower Paratracheal (left)\n\n**AORTIC NODES**\n**AP zone**\n*   5 Subaortic\n*   6 Para-aortic (ascending aorta or phrenic)\n\n**INFERIOR MEDIASTINAL NODES**\n**Subcarinal zone**\n*   7 Subcarinal\n**Lower zone**\n*   8 Paraesophageal (below carina)\n*   9 Pulmonary ligament\n\n**N1 NODES**\n**Hilar/Interlobar zone**\n*   10 Hilar\n*   11 Interlobar\n**Peripheral zone**\n*   12 Lobar\n*   13 Segmental\n*   14 Subsegmental\n\n---\n\n<!-- Page 34 -->\n\n\n\n# NODES STAGING / SPREAD\n\n| A. | B. Superior mediastinal | C. Aortic | D. Inferior mediastinal | E. Hilar and intra pul nodes (N1) nodes |\n| :-- | :----------------------- | :-------- | :---------------------- | :--------------------------------------- |\n| 1. Supraclavicular | 2. Upper paratracheal | 5. Sub aortic | 7. Subcarinal | 10. Hilar |\n| | 3. Prevascular or retrotracheal | 6. Para aortic | 8. Para esophageal | 11. Interlobar |\n| | 4. Lower paratracheal | | 9. Pulmonary ligament | 12. Lobar |\n| | | | | 13. Segmental |\n| | | | | 14. Sub segmental |\n\n*Handwritten notes:*\nEight Esoph\n✓HILSS\n→ HILSS\n\n**N1:** *Ipsilateral peribronchial* and/or *ipsilateral hilar lymph nodes* and *intrapulmonary nodes*.\n\n**N2:** *Ipsilateral mediastinal* and/or *subcarinal lymph node(s)*\n\n**N3:** *Ipsilateral scalene* or *supraclavicular* or *contralateral mediastinal/ hilar/ scalene /supraclavicular lymph node(s)*\n\n---\n\n<!-- Page 35 -->\n\n\n\n# Presence of metastasis is stage IV\n\n**M1a** tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion.\nSeparate tumor nodule(s) in another lung;\n\n**M1b**: Single extra thoracic metastasis in a single organ\n\n**M1c**: Multiple extra thoracic metastases in a single organ or in multiple organs\n\n---\n\n<!-- Page 36 -->\n\nT1a T1b T1c ✓\n\n| Stage      | T         | N         | M   |\n| :--------- | :-------- | :-------- | :-- |\n| (STAGE IA) | Any T1    | (N0)      | M0 ✓ |\n| STAGE IB   | (T2a)     | N0        | M0 ✗ |\n| STAGE IIA  | (T2b)     | N0 ✓      | M0  |\n| STAGE IIB  | _T1/T2_   | (N1)      | M0  |\n|            | (T3)      | N0        | M0  |\n| STAGE IIIA | _T1/T2_   | N2 ✓      | M0  |\n|            | (T3)      | (N1)      | M0  |\n|            | T4        | _N0/N1_   | M0  |\n| STAGE IIIB | T1/T2     | ==N3==    | M0  |\n|            | _T3/T4_   | _N2_      | M0  |\n| STAGE IIIC | T3/T4     | ==N3==    | M0  |\n| STAGE IV   | Any T     | Any N     | M1  |\n\n**Handwritten Notes:**\nStage III Mo\n[Stage IV M1]\n{ un resectable (referring to STAGE IIIB and STAGE IIIC)\n\n---\n\n<!-- Page 37 -->\n\nDr. Bharath Matha\n\n---\n\n<!-- Page 38 -->\n\nManagement of NSCLC\nDr. M. Ravikrishna MD DM\nCONSULTANT MEDICAL & HEMATO ONCOLOGIST ( TMH mumbai )\nKIMS SUNSHINE , BEGUMPET\nHYDERABAD\n\n---\n\n<!-- Page 39 -->",
    "wordCount": 1485,
    "index": 4,
    "subTopicId": "1766794361883-a2w0jmfto"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-5",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "Multidisciplinary tumour board +++",
    "content": "# Multidisciplinary tumour board +++\n\n**Patient**\n\nThe patient is at the center of the multidisciplinary tumour board, with input from various specialties:\n\n*   **Pulmonology**\n    *   Bronchoscopic spread?\n    *   EBUS / EUS?\n    *   Pulmonary function?\n*   **Surgery**\n    *   Feasibility of R0 resection?\n    *   LN single vs. multiple?\n    *   Lobec/pneumonectomy?\n*   **Radiation**\n    *   Radiation field?\n    *   Previous RT?\n    *   Presence ILD?\n*   **Oncology**\n    *   Performance status?\n    *   Organ functions?\n    *   Patient preference?\n*   **Pathology**\n    *   Tumor type?\n    *   PD-L1 expression?\n*   **Imaging**\n    *   Overall spread?\n\nGUSTAVE ROUSSY\nESMO\nESMO ACADEMY\nVIRTUAL MEETING\n\n---\n\n<!-- Page 40 -->\n\n\n\n# Locoregional staging according to 8th edition of TNM\n\nESMO\n\nMetastasis\n\n*   **N0**\n*   **N1:** Ipsilateral peribronchial and/or hilar lymph nodes and intrapulmonary nodes\n*   **N2:** Ipsilateral mediastinal and/or subcarinal lymph nodes\n*   **N3:** Metastasis in contralateral mediastinal, hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes\n\nBrierley JD et al (eds). TNM Classification of Malignant Tumours, 8th edition. John Wiley & Sons, Inc., Oxford, 2016\n\n---\n\n<!-- Page 41 -->\n\n\n\n# For diagnosis and staging\n\n\n\n## Imaging\nThe impact of PET on staging has shown, an up-stage in 16–41%, and down-stage in 6–20% of patients [10,12,13]. Two multi-centric trials have shown that the use of PET could reduce unnecessary thoracotomies in up to 20% of patients with suspected or proven NSCLC [14,15].\n\n\n\n## Tissue\n\n| Parameter | Mandatory | Optional |\n|---|---|---|\n| General | Medical history\\* <br> Physical examination\\* <br> Assessing comorbidity | |\n| Cardio-pulmonary function | FVC, FEV1, DLCO <br> ECG <br> If indicated, CPET | Ejection fraction, CAG |\n| Tissue procurement | Bronchoscopy^§ <br> EBUS/EUS mediastinal nodes\\* <br> CT-guided biopsy ! | Mediastinoscopy |\n\n---\n**Additional Notes/Footnotes (partially visible):**\n\n*   pathological\n*   recommended prior to\n*   treatment\n*   confirmation of\n*   lymph nodes EBUS\n*   EUS does not reveal nodal involvement in a situation of high clinical suspicion, mediastinoscopy indicated\n\n---\n\n<!-- Page 42 -->\n\nKnown or suspected NSCLC\n\n*   **Contrast-Enhanced Chest CT (+liver & adrenal)**\n    *   **Negative / borderline positive Chest CT, clinical stage I/II**\n        *   **FDG PET-CT**\n            *   PET-CT(-) and peripheral cl\n                *   No further mediastinal work-up\n            *   PET-CT(-)\n                *   VATS or EBUS/EUS-NA\n            *   PET-CT(+)\n                *   Tissue confirmation required\n                *   Context-based strategy\n    *   **Massive N2/N3 disease on Chest CT**\n        *   No further mediastinal work-up\n        *   PET CT for metastatic workup\n        *   Context based strategy\n\nMolecular testing – EGFR, ALK PDL1 in stage 1-3, NGS testing in stage 4, MRI brain in all stages except stage IA, IB (optional)\n\n---\n\n<!-- Page 43 -->\n\n```markdown\nCT and PETCT OR PETCT\n↓\nMediastinal nodes Negative\n↓\ncNO and\nperipheral tumor ( outer 1/3rd )\nTsize - < 3 cms\n↓\nSURGERY\n```\n\n---\n\n<!-- Page 44 -->\n\n*   **Initial Imaging:** CT and PETCT OR PETCT\n    *   **Result:** Mediastinal nodes Negative\n\n*   **Further Evaluation (if Mediastinal nodes Negative and specific conditions met):**\n    *   **Conditions:** N1 Or central tumor or Tsize > 4 cms\n    *   **Procedure:** Tissue confirmation (EBUS / EUS Or VAM)\n\n*   **Outcome of Tissue Confirmation:**\n    *   If Mediastinal nodes POSITIVE:\n        *   **Treatment:** MULTIMODALITY TREATMNET\n    *   If Mediastinal nodes Negative:\n        *   **Treatment:** SURGERY\n\n---\n\n<!-- Page 45 -->\n\nCT and PETCT OR PETCT\n*   Mediastinal nodes Negative\n    *   cNO and peripheral tumor (outer 1/3rd) Tsize - < 3 cms\n        *   SURGERY\n    *   N1 Or central tumor Tsize > 4 cms\n        *   Tissue confirmation EBUS / EUS Or VAM\n            *   Mediastinal nodes POSITIVE\n                *   MULTIMODALITY TREATMNET\n            *   Mediastinal nodes Negative\n                *   SURGERY\n\n---\n\n<!-- Page 46 -->\n\n- CT and PETCT OR PETCT\n  - Mediastinal nodes Positive N2\n    - Tissue confirmation EBUS / EUS\n      - Mediastinal nodes POSITIVE\n        - MULTIMODALITY TREATMNET\n          - SURGERY\n      - Mediastinal nodes NEGATIVE\n        - VAM\n          - Mediastinal nodes POSITIVE\n          - Mediastinal nodes NEGATIVE\n            - SURGERY\n\n---\n\n<!-- Page 47 -->\n\nCT and PETCT OR PETCT\n*   Mediastinal nodes Negative\n    *   cNO and peripheral tumor ( outer 1/3rd ) Tsize - < 3 cms\n        *   SURGERY\n    *   N1 Or central tumor Tsize > 4 cms\n        *   Tissue confirmation EBUS / EUS Or VAM\n            *   Mediastinal nodes Negative\n                *   SURGERY\n            *   Mediastinal nodes POSITIVE\n                *   MULTIMODALITY TREATMNET\n*   Mediastinal nodes Positive N2\n    *   Tissue confirmation EBUS / EUS\n        *   Mediastinal nodes POSITIVE\n            *   MULTIMODALITY TREATMNET\n        *   Mediastinal nodes NEGATIVE\n            *   VAM\n                *   Mediastinal nodes POSITIVE\n                    *   MULTIMODALITY TREATMNET\n                *   Mediastinal nodes NEGATIVE\n                    *   SURGERY\n\n---\n\n<!-- Page 48 -->\n\n\n\n# Lung Cancer : Classification\n\nThe image displays a classification of lung cancer stages using a horizontal bar:\n*   **Stage I-II** (grey segment)\n*   **Stage III** (blue segment)\n*   **Stage IV** (red segment)\n\nStage 1&2 : T1-2 N0 , T3 N0, T1-2 N1\nPrimary modality is surgery\n\n---\n\n<!-- Page 49 -->\n\n\n\n# What do the guidelines say?\n\n**Stage IB-IIIA**\n\n*   **R0 resection [I, A]**\n    *   Adjuvant ChT in N+ [I, A]*\n    *   Adjuvant ChT in resected tumours ≥ 4 cm (T2bN0, stage IIA) [II, B]\n*   **R1 resection**\n    *   PORT [IV, B]\n    *   Adjuvant ChT [V, A]\n\n**Chemotherapy Regimens:**\n*   Cisplatin [I, A] in combination with:\n    *   Vinorelbine [I, A]\n    *   Gemcitabine [II, B]\n    *   Docetaxel [II, B]\n    *   Pemetrexed [II, B, non-squamous]\n*   If cisplatin is not feasible, carboplatin is an alternative [IV, B]\n*   If resected primary tumour ≥ 4 cm and N0, carboplatin-paclitaxel [IV, B]\n\n\n\n# LACE Meta-analysis – 5+ year follow up\nN=2380 patients in 5 randomized trials\n\n*   +5.3% survival at 5 years\n*   HR OS: 0.89 (0.82-0.96); P=0.005\n*   HR PFS: 0.84 (0.78-0.91); P<0.001\n\n| STAGE    | Count 1 | Count 2 | Forest Plot Data |\n| :------- | :------ | :------ | :--------------- |\n| Stage IA | 104     | 347     | 0.06, 0.04*      |\n| Stage IB | 515     | 1,371   |                  |\n| Stage II | 893     | 1,616   |                  |\n| Stage III| 878     | 1,247   |                  |\n\n---\n\n<!-- Page 50 -->\n\nAdjuvant cisplatin-based chemotherapy standard in resected stage II, III NSCLC\n(only 59% of eligible patients in Canada receive adjuvant chemotherapy)\n\nLACE meta-analysis: vinorelbine/cisplatin\n\n| Category | OS                               |                               | DFS                               |                               |\n| :------- | :------------------------------- | :---------------------------- | :-------------------------------- | :---------------------------- |\n|          | **No. Deaths / No. Entered**     | **Hazard Ratio [95% CI]**     | **No. Events / No. Entered**      | **Hazard Ratio [95% CI]**     |\n| Stage I  | 238/679                          | 1.01 [0.76, 1.30]             | 298/679                           | 0.95 [0.76, 1.19]             |\n| Stage II | 371/721                          | 0.74 [0.60, 0.91]             | 424/721                           | 0.69 [0.57, 0.83]             |\n| Stage III| 326/488                          | 0.66 [0.53, 0.83]             | 355/488                           | 0.62 [0.50, 0.76]             |\n|          | **Chemotherapy effect: p < 0.001** |                               | **Chemotherapy effect: p < 0.001** |                               |\n|          | Test for heterogeneity: $\\chi^2$ 14.46 p = 0.16 $I^2$ = 31 % | Test for heterogeneity: $\\chi^2$ 15.13 p = 0.13 $I^2$ = 34 % |\n|          | Test for interaction: p = 0.04   | Test for trend: p = 0.02      | Test for interaction: p = 0.02    | Test for trend: p = 0.008     |\n\n**Survival (%) over Time from Randomization (Years)**\n\nLegend:\n*   ... Cisplatin-vinorelbine\n*   ... No chemotherapy\n\n| Stage    | Group                 | 1 Year | 2 Years | 3 Years | 4 Years | 5 Years | $\\ge$ 6 Years |\n| :------- | :-------------------- | :----- | :------ | :------ | :------ | :------ | :------------ |\n| **Stage I** | Cisplatin-vinorelbine |        |         | 74.3    | 68.7    | 64.7    | 59.9          |\n|          | No chemotherapy       |        |         | 73.1    | 66.7    | 59.9    | 54.9          |\n| **Stage II**| Cisplatin-vinorelbine |        |         | 56.2    | 54.4    | 49.9    | 42.8          |\n|          | No chemotherapy       |        |         | 48.2    | 42.8    | 39.9    | 38.7          |\n| **Stage III**| Cisplatin-vinorelbine |        |         | 38.7    | 33.9    | 29.3    | 25.3          |\n|          | No chemotherapy       |        |         | 25.3    | 20.9    | 18.9    | 15.3          |\n\nPignon JP et al J Thorac Oncol 2010; Kris et al J Clin Oncol 2017; Crino et al Ann Oncol 2010; NCCN; CPAC Lung Cancer System Report 2011\n\n---\n\n<!-- Page 51 -->\n\n\n\n# Newer cisplatin doublets have similar outcomes\n\nIn non-squamous NSCLC, pemetrexed/cisplatin less toxic than vinorelbine/cisplatin\n\n**ECOG1505 (+/- bevacizumab)**\nN=1501, resected IB >=4cm-IIIA 7th edition\n\n**JIPANG (nonsquamous)**\nN= 804, resected II-IIIA 7th edition\n\n\n\n## Overall Survival Probability (ECOG1505)\n\n\n\n### NonSquam, All Pts regardless of +/- Bev\n\n| Treatment | Events | Cases |\n| :-------- | :----- | :---- |\n| Cis/Doce  | 101    | 202   |\n| Cis/Gem   | 61     | 134   |\n| Cis/Pem   | 186    | 494   |\n| Cis/Vin   | 104    | 248   |",
    "wordCount": 1421,
    "index": 5,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-6",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "Squam, All Pts regardless of +/- Bev",
    "content": "### Squam, All Pts regardless of +/- Bev\n\n| Treatment | Events | Cases |\n| :-------- | :----- | :---- |\n| Cis/Doce  | 61     | 143   |\n| Cis/Gem   | 62     | 151   |\n| Cis/Vin   | 50     | 128   |\n\n\n\n## Overall Survival (%) (JIPANG)\n\n*   Vinorelbine plus cisplatin\n*   Pemetrexed plus cisplatin\n*   HR, 0.98 (95% CI, 0.71 to 1.35)\n*   P = .434 (1-sided)\n\nVinorelbine/cisplatin more toxic\nFebrile neutropenia 11.6% v 0.3%\n\n---\nWakelee...Leighi et al WCLC 2019; Wakelee, Leighl et al Lancet Oncol 2017; Kenmotsu et al J Clin Oncol 2020\n\n---\n\n<!-- Page 52 -->\n\n\n\n# What is the evidence in T >=4 cm N0 resected NSCLC?\n\n\n\n## CALGB 9633 – resected T2N0 7th edition\nAdjuvant carboplatin/paclitaxel\n\n![CALGB 9633 Survival Probability Graph](image_crop_4.png)\n\n*   **Chemotherapy** (N = 99)\n*   **Control** (N = 97)\n*   HR = 0.69\n*   90% CI: 0.48 to 0.99\n*   P = .043\n*   **Time (Months)**\n*   **Survival Probability**\n\nT<4 cm OS HR: 1.12 p NS\n\n\n\n## NCIC CTG JBR.10 – subgroup analysis\nAdjuvant cisplatin/vinorelbine (N=120)\n\n\n\n### Stage 1B and Tumor Diameter ≥ 4 cm\n![NCIC CTG JBR.10 Survival Probability Graph](image_crop_5.png)\n\n*   **Observation**\n*   **Chemotherapy**\n*   Log rank: P = .133\n*   HR 0.66 (95% CI, 0.39 to 1.14)\n*   **Time (years)**\n\nT<4 cm OS HR: 1.73 p=0.056\n\n\n\n## Size remains key predictor\n\n\n\n### JBR.10 Exploratory Analysis of Pathologic Factors in T2N0 (n=217)\n\n| Factor                                                              | HR [95% CI]      | p-value |\n| :------------------------------------------------------------------ | :--------------- | :------ |\n| Tumor Size ≥4cm\\*                                                   | 2.4 [1.2-4.8]    | p=0.008 |\n| High LDH                                                            | 3.1 [1.6-6.3]    | p=0.001 |\n| Moderate Inflammation                                               | 2.3 [1.1-4.8]    | p=0.02  |\n| Moderate Fibrosis                                                   | 2.7 [1.3-5.8]    | p=0.007 |\n| Lymphatic Invasion\\*                                                | 0.46 [0.25-1.2]  | p=0.11  |\n| Vascular Invasion                                                   | 0.39 [0.1-1.4]   | p=0.15  |\n| *Note: Visceral Pleural Involvement Neither Prognostic nor Predictive of Benefit* |                  |         |\n\n---\nStrauss et al J Clin Oncol 2008, Butts et al J Clin Oncol 2009, Strevel et al ASCO 2007\n\n---\n\n<!-- Page 53 -->\n\nShift to 8th edition: >4cm tumors now stage II – easy!!\n\n| TNM 7<sup>th</sup> EDITION | TNM 8<sup>th</sup> EDITION |\n| :---------------------- | :-------------------- |\n| **T**                   |                       |\n|                         | Tis                   |\n|                         | Tmi                   |\n|                         | Tss                   |\n| T1a (≤2 cm)             | T1a (≤1 cm)           |\n| T1b (>2-3 cm)           | T1b (>1-2cm)          |\n|                         | T1c (>2-3cm)          |\n| T2a (>3-5 cm)           | T2a (>3cm but ≤4cm)   |\n| T2b (>5-7 cm)           | T2b (>4cm but ≤5cm)   |\n| T3 (>7 cm)              | T4                    |\n| T3 - atelectasis/pneumonitis involving whole lung) | T2 atelectasis/pneumonitis irrespective of involving lobe or whole lung |\n| T3 tumor involving the main bronchus <2cm distance to carina | T2 -tumor involving the main bronchus irrespective of distance to carina |\n| T3 -invasion of the diaphragm | T4 (invasion of the diaphragm) |\n| **N** No changes        |                       |\n| **M** M1b - distant metastasis | M1b - single extrathoracic metastasis |\n|                         | M1c - multiple extrathoracic metastases |\n\n|       | N0    | N1    | N2    | N3    |\n| :---- | :---- | :---- | :---- | :---- |\n| **T1**  | IA    | IIB   | IIIA  | IIIB  |\n| **T2a** | IB    | IIB   | IIIA  | IIIB  |\n| **T2b** | IIA   | IIB   | IIIA  | IIIB  |\n| **T3**  | IIB   | IIIA  | IIIB  | IIIC  |\n| **T4**  | IIIA  | IIIA  | IIIB  | IIIC  |\n| **M1a** | IVA   | IVA   | IVA   | IVA   |\n| **M1b** | IVA   | IVA   | IVA   | IVA   |\n| **M1c** | IVB   | IVB   | IVB   | IVB   |\n\n---\n\n<!-- Page 54 -->\n\n\n\n# What about Radiation?\nPORT Meta-Analysis (N 2128; 9 RCTs)\n\n% patients\n100\n80\n60\n40\n20\n0\n\nSurvival Time (Months)\n0 12 24 36 48 60\n\n-No PORT\n55%\n48%\n\nPORT detrimental in stage 1, 2\nPORT better in N2 but non-significant trend\n\nPORT Meta-analysis Trialists Group Lancet 1998\n\n---\n\n<!-- Page 55 -->\n\n\n\n# Adjuvant Chemotherapy in Early Non-small cell Lung Cancer\n\n\n\n## Indications for Adjuvant chemotherapy-\n\n*   Stage IIA to IIIA i.e., any tumor more than 4cm and/or N1 or N2 node positive as per current 8th AJCC TNM\n*   Stage I lung cancer with a tumor size 4cm (stage IB), poorly differentiated histology, vascular or lymphatic invasion, visceral pleura invasion may be considered for adjuvant chemotherapy.\n*   Other factors to consider for those eligible for adjuvant chemotherapy includes timing within 4 – 6 weeks of surgery, performance status ECOG 0 or 1, comorbidity.\n\n---\n\n<!-- Page 56 -->\n\n\n\n# Which regimen to choose?\n\n\n## Adjuvant Chemotherapy Regimens\n\n*   For non-squamous NSCLC the preferred regimen is cisplatin +pemetrexed based combination\n*   For the squamous variant, cisplatin with gemcitabine or docetaxel is preferred, other recommended options include cisplatin +vinorelbine, cisplatin +etoposide.\n\nFor patients with comorbidities making them cisplatin ineligible, carboplatin may be used instead of cisplatin.\n\n---\n\n<!-- Page 57 -->\n\nWhat is the option for those who are EGFR mutation positive?\n\n**Adjuvant Osimertinib** should be considered for duration of **36 months** in resected non-squamous NSCLC Stage II to III (AJCC 8th edition) carrying sensitizing EGFR (Exon 19 del or Exon 21 L858R) irrespective of feasibility of adjuvant platinum-based chemotherapy.\n\nBased on this it is now standard practice to test these patients for EGFR mutation.\n\nSimilarly, at present though there is no recommendation for adjuvant ALK directed therapy, but studies are ongoing and soon may change our current approach for these patients too.\n\n---\n\n<!-- Page 58 -->\n\nWhat is new?\n\nImpoweR010, has shown remarkable disease-free survival advantage with **Atezolizumab for 1 year after adjuvant chemotherapy** as consolidation over best supportive care in **stage II to IIIA completely resected patients with PDL1 more than 1%**.\n\nThis is now approved by FDA, NCCN and EMA for eligible patients based on this study\n\n---\n\n<!-- Page 59 -->\n\nLung Cancer : Classification\n\nStage I-II | Stage III | Stage IV\n\nStage III : T3 N1-N3 -T4 N0-3\n\n---\n\n<!-- Page 60 -->\n\nA Case...\n* 60 year old male, ex-smoker (20 pack years, quit 23 years ago), retired teacher, well (controlled BP, cholesterol)\n* Referred to thoracic surgery based on \"routine\" CT\n* 6 mm LUL semisolid nodule in periphery of rt lung lower lobe – followed for 3 months --> minor growth\n* Biopsy: adenocarcinoma\n* Preoperative PET: no avid disease\n* Underwent VATS lobectomy (ctDNA detected preop in \"ctDNA Detect\" clinical trial)\n\nPathology: LUL 1.2 cm adenocarcinoma, LVI+, station 4R+ TP53 mutation, PD-L1<1%: T1bN2 or IIIA NSCLC\n\nBP: blood pressure, LUL: left upper lobe; PET: positron emission tomography; VATS: video assisted thoracoscopy; LVI: lymphovascular invasion; PD-L1: programmed death ligand-1\n\n---\n\n<!-- Page 61 -->\n\n\n\n# Incidental' N2 disease\n\nWhen the SMLND yields positive N2 nodes, despite an adequate pre-operative invasive mediastinal staging; the patient should receive adjuvant chemotherapy after a meticulous R0 resection.\n\n- The reason for this could be micro metastases, involvement of inferior pulmonary ligament or aortapulmonary ligament nodes which cannot be sampled by routine techniques or a false negative invasive staging.\n\nADJUVANT chemo with 4# 3 weekly once pemetrexed + cisplatin or gemcitabine + cisplatin\n\n---\n\n<!-- Page 62 -->\n\nResectable- Locally advanced\nIIIA\nN2 -not bulky\n\n---\n\n<!-- Page 63 -->\n\nSingle station, resectable N2 disease\n\nSurgery remains an integral part of the multimodality treatment algorithm.\n\nThis disease mandates chemotherapy, either neoadjuvant or adjuvant. Most of the available evidence favours neo-adjuvant chemotherapy followed by surgery. Neo-adjuvant chemoradiation has also been instituted with good results in some centers.\n\nSome centers prescribe a restaging mediastinoscopy post neo-adjuvant therapy for N2 disease; a persistent positive N2 precluding surgical resection. However, the nay-sayers to this approach maintain that in disease that has not responded to chemotherapy +/-radiation, surgery remains the only curative treatment option.\n\nNeo -ADJUVANT chemo with 4# 3 weekly once pemetrexed + cisplatin or gemcitabine + cisplatin f/b surgery\n\n---\n\n<!-- Page 64 -->\n\n\n\n# UNRESECTABLE\n\n**N3 disease -**\n*   Involvement of contralateral mediastinal nodes or supraclavicular nodes\n*   Consensus is for treatment with **definitive chemoradiation** with adjuvant **Durvalumab** where feasible\n\n**Multistation, bulky N2 disease -**\n*   Multiple ipsilateral mediastinal stations involved with large, 'bulky' nodes\n*   Best treated with **definitive chemoradiation followed by Durvalumab**\n\n**Unresectable N2 disease -**\n*   The definition of 'unresectable' is not standardized.\n*   Most centers consider mediastinal nodes > 3 cm in diameter as bulky or unresectable.\n*   The recommendation for this disease is treatment with **definitive chemoradiation followed by Durvalumab.**\n\n**Definitive CTRT f/b durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months)**\n\n---\n\n<!-- Page 65 -->\n\nN2 disease\n*   **If Single station, Resectable:**\n    *   Neo-adjuvant Chemotherapy chemoradiation\n    *   Surgery\n*   **If Single station, unresectable:**\n    *   Definitive Chemoradiation & Durvalumab\n    *   Residual Disease\n    *   Surgery\n*   **If Multistation:**\n    *   Definitive Chemoradiation & Durvalumab\n    *   Residual Disease\n    *   Surgery\n*   **If Incidental:**\n    *   Adjuvant Chemotherapy\n\n---\n\n<!-- Page 66 -->",
    "wordCount": 1501,
    "index": 6,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-7",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "Locally Advanced Primary Tumour",
    "content": "# Locally Advanced Primary Tumour\n\n\n\n## Chest wall/ Pericardial invasion - Included in T3 tumours. -\n\n*   -Surgery is feasible and safe, if a complete (R0) resection can be ensured.\n*   -Shallow invasion (parietal pleura) may be dealt with by extrapleural dissection while deeper invasion warrants en bloc resection of soft tissue and ribs.\n*   -En bloc resections have a higher morbidity and mortality compared to standard lobectomy.\n*   -Long-term survival in completely resected patients ranges from 36-67% in those with T3N0 while survival drops to <10% in N2 disease, emphasizing diligent staging and patient selection.\n\n---\n\n<!-- Page 67 -->\n\n**Diaphragm invasion:** -\n*   Included in T4 tumours\n*   En bloc resection of the diaphragm is safe and offers chance of cure in selected patients.\n*   Completely resected cases with diaphragmatic invasion have a long-term survival ranging from 20-43% in T4N0 stages.\n*   There is no established role for neo-adjuvant or adjuvant treatment on account of chest wall, pericardial or diaphragmatic invasion alone.\n*   Neo-adjuvant treatment depends on the N2 nodal status.\n*   Adjuvant treatment is dictated by the tumour size and nodal status.\n\n---\n\n<!-- Page 68 -->\n\nDiaphragm invasion: -\nIncluded in T4 tumours\n\nEn bloc resection of the diaphragm is safe and offers chance of cure in selected patients.\n\nCompletely resected cases with diaphragmatic invasion have a long-term survival ranging from 20-43% in T4N0 stages.\n\nThere is no established role for neo-adjuvant or adjuvant treatment on account of chest wall, pericardial or diaphragmatic invasion alone.\n\nNeo-adjuvant treatment depends on the N2 nodal status.\n\nAdjuvant treatment is dictated by the tumour size and nodal status.\n\n---\n\n<!-- Page 69 -->\n\n\n\n# Superior sulcus/ Pancoast tumour: -\n\n-Include tumours infiltrating the posterior part of apical pleuropulmonary groove and involving structures of the thoracic inlet such as subclavian vessels, brachial plexus, stellate ganglion, etc.\n\ninduction chemoradiation followed by surgery.\n\nSurgery is usually undertaken 3-5 weeks after induction therapy.\n\nIt entails en bloc resection of involved structures by a posterior or anterior approach.\n\nSurgery is contraindicated in extensive involvement of brachial plexus, intraspinal extension, soft tissues of the neck and N2/N3 disease.\n\n---\n\n<!-- Page 70 -->\n\n\n\n# CHEMOTHERAPY indications\n\n\n\n## ADJUVANT\n*   Stage IB - poorly differentiated histology, vascular or lymphatic invasion, visceral pleura invasion\n*   Stage IIA to IIIA\n\n\n\n## Scenarios in which NACT may be considered\n*   In potentially resectable disease especially those with single-station mediastinal nodal involvement,\n*   Superior sulcus tumors\n*   Chest wall invasion in the setting of N1 nodal involvement\n\n---\n\n<!-- Page 71 -->\n\n\n\n# Radiotherapy in Locally Advanced Lung Cancer Indications:\n\n\n\n## DEFINITIVE CTRT\n- Unresectable lung primary - N2 (Bulky, single station / Multistation) and N3 disease\n- Patients not fit/ willing for surgery\n\n\n\n## ADJUVANT\n- As adjuvant for node positive disease (persistent N2/multiple node positive/ with ENE) or positive margins\n\n\n\n## NEOADJUVANT\n- As neoadjuvant chemoradiation followed by resection in superior sulcus tumor\n\n---\n\n<!-- Page 72 -->\n\n\n\n# Periadjvant therapy outcomes by PD-L1 (<1%) – adjuvant/neoadjuvant chemotherapy remains the treatment of choice for some patients\n\n\n\n## NADIM II\n(pCR 15% in PD-L1<1%)\n\nA box plot showing PD-L1 TPS (Tumour Proportion Score) on the y-axis versus Pathological response on the x-axis.\n*   **Complete response:** Higher median PD-L1 TPS, with a wider range.\n*   **Incomplete - major response:** Lower median PD-L1 TPS, with a narrower range.\n*   T-test, p = 0.0058.\n\n\n\n## CheckMate 816 (EFS)\n\n| PD-L1 <1%   | Nivo + chemo (n=78) | Chemo (n=77) |\n| :---------- | :-------------------- | :----------- |\n| mEFS, months | 25.1                  | 18.4         |\n| HR (95% CI) | 0.85 (0.54, 1.32)     |              |\n\nA Kaplan-Meier curve showing Event-Free Survival (EFS) percentage over months from randomisation.\n*   **Nivo + chemo (blue line):**\n    *   At 12 months: ~69% EFS\n    *   At 24 months: ~52% EFS\n*   **Chemo (red line):**\n    *   At 12 months: ~66% EFS\n    *   At 24 months: ~40% EFS\n\n\n\n## IMpower010 (OS)\n\nA forest plot showing Hazard Ratios (HR) for Overall Survival (OS) across various subgroups.\n\n| Subgroup                  | n   | HR (95% CI)       |\n| :------------------------ | :-- | :---------------- |\n| All patients              | 881 | 0.79 (0.64, 0.96) |\n| **Stage**                 |     |                   |\n| IA                        | 295 | 1.08 (0.68, 1.69) |\n| IB                        | 174 | 0.88 (0.54, 1.42) |\n| IIA                       | 413 | 0.63 (0.44, 0.90) |\n| **Regional lymph node stage (pN)** |     |                   |\n| N0                        | 229 | 1.08 (0.67, 1.73) |\n| N1                        | 174 | 0.87 (0.47, 1.60) |\n| N2                        | 305 | 0.63 (0.41, 1.10) |\n| **SPSS PD-L1 status**     |     |                   |\n| TC ≥50%                   | 229 | 0.49 (0.27, 0.88) |\n| TC ≥1%                    | 476 | 0.88 (0.64, 1.20) |\n| TC <1%                    | 385 | 1.07 (0.75, 1.52) |\n| **EGFR mutation status**  |     |                   |\n| Yes                       | 108 | 1.09 (0.60, 1.97) |\n| No                        | 560 | 0.80 (0.60, 1.06) |\n| Unknown                   | 113 | 0.70 (0.40, 1.24) |\n| **ALK rearrangement status** |     |                   |\n| Yes                       | 15  | 1.34 (0.38, 4.70) |\n| No                        | 527 | 0.83 (0.61, 1.13) |\n| Unknown                   | 344 | 0.77 (0.54, 1.10) |\n\n*   **Legend:** Atezolizumab better (left side of HR 1.0) | SOC better (right side of HR 1.0)\n\n---\n**Abbreviations:**\nChemo, chemotherapy; CI, confidence interval; (m)EFS, (median) event-free survival; HR, hazard ratio; nivo, nivolumab; pCR, pathological complete response; PD-L1, programmed cell death ligand-1; TPS, tumour proportion score.\n\n**References:**\n1.  Provencio M, et al. Presented at ASCO 2022 (Abstract 8501).\n2.  Girard N, et al. Presented at AACR 2022 (Abstract CT012).\n3.  Felip et al Lancet Oncol 2022.\n\n---\n\n<!-- Page 73 -->\n\nThere is no text to extract from the provided image, as it appears to be a blank grid or graph paper.\n\n---\n\n<!-- Page 74 -->\n\nLung Cancer : Classification\n\n| Stage I-II | Stage III | Stage IV |\n| :--------- | :-------- | :------- |\n\nStage4 – EGFR , ALK , ROS , PDL1 , BRAF , MET\n\n---\n\n<!-- Page 75 -->\n\n\n\n# WORK FLOW\n\nStage 4 lung carcinoma\n\nCheck biopsy report\nSquamous cell carcinoma or adeno ca\n\nIf squamous cell carcinoma –\n*   IHC for PDL1\n*   RTPCR FOR EGFR\n*   NGS – 12 gene / 52 gene / CGP ( based on affordability )\n\nIf adeno ca --\n*   IHC for ALK , ROS , PDL1\n*   RT PCR FOR EGFR\n*   NGS – 12 gene / 52 gene / CGP ( based on affordability )\n\nIf asyymptomatic -\n*   Wait for NGS or molecular reports and then start therapy based on report\n\nIf symptomatic –\n*   start chemo ( pemetrexed + carboplatin for adenoca ) , gemcitabine + carboplatin ( squamous cell ca )\n\nTrace molecular reports before cycle 2 and modify therapy based on reports\n\n---\n\n<!-- Page 76 -->\n\n\n\n# TARGETABLE BIOMARKERS IN NSCLC\n\n**Oncogenic addiction**\n\n*   NTRK\n*   ALK\n*   RET\n*   EGFR:\n    *   Ins exon 20\n    *   S768L, G719X, L861Q\n    *   del 19/L858R\n*   HER2 ins exon 20\n*   ROS\n\n*   Met Exon 14\n*   BRAF V600\n\n**Onco-immunogenicity**\n\n*   KRAS\n\nTumor heterogeneity, a gradient from oncogenic addiction to immunogenicity\n\n---\n\n<!-- Page 77 -->\n\n\n\n# Incidence of $\\text{EGFR}$ Mutations in Indian Lung Cancer -- a Study of 907 Patients\n\nWe studied incidence of known $\\text{EGFR}$ mutations in 907 lung cancer patients using Sanger sequencing and TaqMan based real time PCR.\n\n**Summary of $\\text{EGFR}$ Mutation Incidence:**\n\n*   **Non-small cell lung cancer (NSCLC)**\n    *   Total patients: n=907\n    *   $\\text{EGFR}$ mutant: 23%\n    *   $\\text{EGFR}$ wild-type: 77%\n\n*   **Other NSCLC Subtypes**\n    *   Others: n=24\n    *   Squamous: n=103\n        *   $\\text{EGFR}$ mutant: 3.8%\n\n*   **Adenocarcinoma**\n    *   Total patients: n=780\n    *   $\\text{EGFR}$ mutant: 26%\n    *   $\\text{EGFR}$ wild-type: 74%\n\n*   **Adenocarcinoma by Sex (n=780 cohort)**\n    *   Female Adenocarcinoma: n=249\n        *   $\\text{EGFR}$ mutant: 32%\n        *   $\\text{EGFR}$ wild-type: 68%\n    *   Male Adenocarcinoma: n=531\n        *   $\\text{EGFR}$ mutant: 23%\n        *   $\\text{EGFR}$ wild-type: 77%\n\n*   **Adenocarcinoma by Sex (n=477 cohort)**\n    *   Female Adenocarcinoma: n=244\n        *   $\\text{EGFR}$ mutant: 17%\n        *   $\\text{EGFR}$ wild-type: 83%\n    *   Male Adenocarcinoma: n=233\n        *   $\\text{EGFR}$ mutant: 30%\n        *   $\\text{EGFR}$ wild-type: 70%\n\n23% incidence of $\\text{EGFR}$ mutation was observed in NSCLC patients of Indian ethnicity, in contrast to 10-15% known in Caucasians.\n\nChougule A. et al., PLOS One 2013\n\n---\n\n<!-- Page 78 -->\n\nTesting for EGFR mutation - Methods used for diagnosis of EGFR mutation are\n* quantitative Polymerase Chain reaction (qPCR),\n* Next Generation Sequencing (NGS) and Sanger sequencing. -\n* EGFR expression by immunohistochemistry (IHC) is not a recommended method for diagnosis of EGFR mutation.\n\nEGFR copy number analysis (i.e by FISH/CISH) should not be used to select patients for targeted TKI therapy.\n\n- As far as use of cell-free DNA (cf DNA) is concerned, there is insufficient evidence for its use for diagnosis. In situations when the tissue is limited or insufficient it may be used to identify EGFR mutation.\n\ncf DNA can be used for diagnosis of secondary mutations of T790M on progression.\n\n---\n\n<!-- Page 79 -->",
    "wordCount": 1497,
    "index": 7,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-8",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "EGFR Mutations in NSCLC",
    "content": "## EGFR Mutations in NSCLC",
    "wordCount": 5,
    "index": 8,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-9",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "| Exon location | Common mutations (%)    | Rare m",
    "content": "| Exon location | Common mutations (%)    | Rare mutations (%)",
    "wordCount": 11,
    "index": 9,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-10",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 80 -->",
    "wordCount": 5,
    "index": 10,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-11",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "EGFR Tyrosine Kinase Inhibitors",
    "content": "# EGFR Tyrosine Kinase Inhibitors\n\nOsimertinib is superior to 1st generation TKIs and has CNS activity, hence it is considered as a preferred option in first line treatment for NSCLC with sensitizing EGFR mutation. However, its cost is a major hindrance for its universal usage.\n\n| EGFR TKI | Type of | Indication |\n|---|---|---|\n| Erlotinib | | |\n| **Second generation TKI** | Irreversible | First line therapy |\n| Afatinib | | |\n| Dacomitinib | | |\n| **Third generation TKI** | Irreversible | First line therapy |\n| Osimertinib | | Second line therapy for T790M mutation |\n\n---\n\n<!-- Page 81 -->\n\n\n\n## Options for first-line treatment of EGFR mutant advanced NSCLC -\n\n*   1) Osimertinib- preferred choice due to its efficacy (superior PFS, OS), CNS activity, safety and tolerability.\n*   2) Gefitinib + Chemotherapy- first line option in fit patients, especially in LMICs where most patients do not have access to Osimertinib\n*   3) Dacomitinib\n*   4) Gefitinib, Erlotinib- 1 st generation TKIs alone may be considered in patients who are elderly, por performance status>2\n*   5) Afatinib-preferred in certain rare mutations based on data from pooled analysis of Lux Lung 3 & 6 trials\n*   6) Erlotinib + Bevacizumab\n\n---\n\n<!-- Page 82 -->\n\n\n\n# ALK Mutation- Incidence\n\nOriginal Article\n*ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India*\nAmanjit Bal, Navneet Singh, Parimal Agarwal, Ashim Das, Digambar Behera\nFirst published: 08 August 2016 | https://doi.org/10.1111/apm.12581 | Citations: 6\n\n*ALK* gene rearrangement in the lung adenocarcinomas is the second most common (1.6–11.7% of NSCLC) targetable genomic change after *EGFR* mutations¹.\n\n**Mutation Incidence (from pie chart):**\n*   No oncogenic driver identified: 38%\n*   KRAS: 25%\n*   EGFR: 23%\n*   ALK: 7.8%\n*   ERBB2: 2.7%\n*   BRAF: 2.0%\n*   PIK3CA: 0.8%\n*   NRAS: 0.7%\n*   MET: 0.7%\n*   MEK1: 0.3%\n\nAdapted from Journal of Thoracic Oncology, 2015\n\n---\n¹ Bal A, Singh N, Agarwal P, Das A, Behera D. APMIS. 2016 Oct;124(10):832-8.\n\n---\n\n<!-- Page 83 -->\n\n\n\n# ALK Rearrangements in Lung Cancer\n\nApproximately 5% of all NSCLC cases$^1$\n*   Typically, adenocarcinoma histology.\n*   Typically (but not always) never smokers or light former smokers.\n*   Tend to occur in younger patient\n*   Diagnostic techniques available\n*   EML4-ALK and EGFR mutations are mutually exclusive\n\nDifferent variants of EML4-ALK and non-EML4 fusion partners$^3$\n\n| Fusion Type | Fusion Partner | ALK | Coiled-coil domain | Tyrosine kinase domain |\n| :---------- | :------------- | :-- | :---------------- | :------------------ |\n| EML4-ALK    |                |     |                   |                     |\n| E13;A20     | EML4           | ALK |                   |                     |\n| E6;A20      | EML4           | ALK |                   |                     |\n| E20;A20     | EML4           | ALK |                   |                     |\n| E14;A20     | EML4           | ALK |                   |                     |\n| E18;A20     | EML4           | ALK |                   |                     |\n| E15;A20     | EML4           | ALK |                   |                     |\n| E2;A20      | EML4           | ALK |                   |                     |\n| E17;A20     | EML4           | ALK |                   |                     |\n| TFG-ALK     | TFG            | ALK |                   |                     |\n| KIF5B-ALK   | KIF5B          | ALK |                   |                     |\n\n**Legend:**\n*   Coiled-coil domain\n*   Tyrosine kinase domain\n\nAdapted from Journal of Thoracic Oncology, 2015\n\nAdapted from Sasaki T et al. Eur J Cancer 2010\n\nPlease see summary of prescribing information on last slide\n\n1.  Sasaki T et al. Eur J Cancer. 2010 July; 46(10): 1773–1780.\n\n---\n\n<!-- Page 84 -->\n\n\n\n# Testing for ALK Fusions -\n\n**Break-apart fluorescent in situ hybridization (FISH)** was established as the gold standard test to identify ALK gene rearrangement.\n\n- The close association between a positive FISH test and modestly elevated ALK protein in tumor cells allows ALK immunohistochemistry (IHC) to be used routinely for testing.\n- In the present algorithm for ALK testing, **IHC with Ventana D5F3 antibody is used as the first test**, in cases of **1+ or 2+ scoring, FISH is used as a confirmatory test**. Strong granular cytoplasmic staining in any percentage of positive tumor cells is regarded as **3+ and is a candidate for ALK inhibitor**.\n- With increasing use of Next Generation sequencing (NGS), if the turnaround time is optimal (preferably up to two weeks), RNA-based NGS is an ideal test to be conducted at baseline in all patients of NSCLC.\n\n---\n\n<!-- Page 85 -->\n\nALK REARRANGEMENT POSITIVEᵐᵐ\n\nALK rearrangement positive\n*   ALK rearrangement discovered prior to first-line systemic therapy\n    *   FIRST-LINE THERAPYᵖᵖ\n        *   **Preferred**\n            *   Alectinibᵠᵠ (category 1)\n            *   or\n            *   Brigatinibᵠᵠ (category 1)\n            *   or\n            *   Lorlatinibᵠᵠ (category 1)\n        *   **Other Recommended**\n            *   Ceritinibᵠᵠ (category 1)\n        *   **Useful In Certain Circumstances**\n            *   Crizotinibᵠᵠ (category 1)\n    *   Progression -> Subsequent Therapy (NSCL-27)\n    *   Progression -> Subsequent Therapy (NSCL-28)\n*   ALK rearrangement discovered during first-line systemic therapy\n    *   Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib\n    *   Progression -> Subsequent Therapy (NSCL-27)\n    *   or\n    *   crizotinib\n    *   Progression -> Subsequent Therapy (NSCL-28)\n\n---\n\n<!-- Page 86 -->\n\n**ROS MUTATED**",
    "wordCount": 833,
    "index": 11,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-12",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "Techniques for the detection of ROS-1 rearrangements",
    "content": "### Techniques for the detection of ROS-1 rearrangements",
    "wordCount": 8,
    "index": 12,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-13",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "| Technique | Advantages",
    "content": "| Technique | Advantages",
    "wordCount": 4,
    "index": 13,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-14",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 87 -->",
    "wordCount": 5,
    "index": 14,
    "subTopicId": "1766794361883-ywzis95ke"
  },
  {
    "id": "61-diagnsis-staging-mx-ocr-complete--1--chunk-15",
    "bookId": "61-diagnsis-staging-mx-ocr-complete--1-",
    "sectionTitle": "RET fusion kinase inhibitors",
    "content": "# RET fusion kinase inhibitors\n\n| Trial | LIBRETTO-001 (phase I/II) | ARROW (Phase I/II) |\n|---|---|---|\n| **Drug & Dose** | Selpercatinib | Pralsetinib |\n| | <50 kg: 160 mg | 400 mg PO once- |\n| | >50 kg: 120 mg PO | daily on an empty |\n| | twice daily (approx. | stomach |\n| | every 12 hours), with or | |\n| | without food | |\n| **Population & No of pts.** | • RET fusion-positive NSCLC | • Treatment naive=27 |\n| | • Treatment naive=39 | • Previous platinum treatment=87 |\n| | • Previous platinum treatment=105 | |\n| **Response Rates** | • 85% | • 70% |\n| | • 64% | • 61% |\n| **Duration of Response (DOR)** | • 90% responses last for at least 6 months | • 58 % of responses lasting at least 6 months (median DOR -9 months) |\n| | • 63% lasting for 12.1 months (median DOR 18 months) | • Median DOR not achieved, 80 % of responses lasted at least 6 months |\n| **Adverse Events** | • Grade 3-4: 58% | • Grade 3 to 4: 2 % |\n| | hypertension: 14%, raised AST: 10% | hypertension 14 % |\n| | • Hyponatremia: 6% | pneumonia 8 %, |\n| | • Lymphopenia: 6% | diarrhea 3%, |\n| | • Fatal adverse events: 4% | fatigue 2%. |\n| | • Others: QTc Prolongation | • Fatal adverse events: 5% |\n\n*Selpercatinib and Pralsetinib had activity in patients with brain metastases.*\n\n\n\n# MET inhibitors\n\n| Drug | N | Dose | Line of Rx | RR (%) | DOR | PFS | OS Months | discontinuation due to TRAE (%) | Toxicity |\n|---|---|---|---|---|---|---|---|---|---|\n| Crizotinib | 65 | 250mg BD | 1 or | 32 | 9.1 | 7.3 | 20.5 | 7 | vision disorders, nausea, diarrhea, vomiting, edema, constipation, transaminitis, fatigue, dizziness, neuropathy |\n| | | | >1 | | | | | | |\n| Capmatinib (FDA approved) | 63 | 400mg BD | 1 or | 68 | 12.6 | 10.8 | 20.8 | 11 | peripheral edema, nausea, vomiting, raised creatinine. |\n| | | | >1 | 41 | 9.7 | 6.9 | 13.6 | | |\n| Tepotinib (FDA approved) | 152 | 500 mg once daily | 1 or | 44.9 | 10.8 | 8.9 (overall) | 17.1 (overall) | 11 | peripheral edema, diarrhea, musculoskeletal pain, dyspnea |\n| | | | >1 | 46.6 | 11.1 | | | | |\n| Savolitinib | 61 | 400, 600 mg | 1 or | 54.4 | 6.8 | 13.8 | NA | 14.3 | peripheral edema, transaminitis, nausea, vomiting, hypoalbumin |\n| | | | >1 | 46 | NR | 5.6 | | | |\n\n---\n\n<!-- Page 88 -->\n\nStage IV lung carcinoma with BRAF V600 mutation\n*   Dabrafenib/trametinib [III, A; MCBS 2]\\*\n    *   or\n*   Platinum-based ChT [IV, A]\n\n**Disease progression**\n\n*   **Oligoprogression**\n    *   Local treatment\n    *   → Systemic progression\n*   **Systemic progression**\n    *   Dabrafenib/trametinib [III, A; MCBS 2]\\*\n        *   or\n    *   Platinum-based ChT [IV, A] (see Figure 2) if BRAF/MEK inhibitors received in first line\n    *   Consider immunochemotherapy as per Figure 2 if smoker [IV, B]\n\n---\n\n<!-- Page 89 -->\n\n\n\n# SCENARIO IN 2023\n\n*   **EGFR**\n    *   Osimertinib\n    *   Gefitinib\n    *   Erlotinib\n    *   Afatinib\n    *   Patritumab\n    *   Deruxtecan\n    *   Amivantamab\n    *   Lazeritinib\n*   **ALK**\n    *   Alectinib\n    *   Crizotinib\n    *   Brigatinib\n    *   Lorlatinib\n    *   Certinib\n    *   Ensartinib\n*   **ROS1**\n    *   Crizotinib\n    *   Entrectinib\n    *   Lorlatinib\n    *   Repotrectinib\n*   **BRAF**\n    *   Dabrafenib\n    *   Trametinib\n*   **RET**\n    *   Selpercatinib\n    *   Pralsetinib\n*   **HER2**\n    *   Trastuzumab\n    *   Deruxtecan\n    *   Poziotinib\n*   **EGFRex20**\n    *   Mobocertinib\n    *   Amivantamab\n*   **METex14**\n    *   Tepotinib\n    *   Capmatinib\n*   **NTRK**\n    *   Larotrectinib\n    *   Entrectinib\n*   **KRAS**\n    *   Sotorasib\n    *   Adagrasib\n*   **CLIP1**\n    *   Lorlatinib\n\n---\n\n<!-- Page 90 -->\n\n\n\n# 2024 IMMUNOTHERAPY TREATMENT OPTIONS\n\n\n## ADVANCED NSCLC\n\n**Advanced NSCLC without driver alteration**\n\n*   **PD-L1 >50%**\n    *   ICI + chemotherapy\n    *   ICI monotherapy\n    *   ICI combo therapy (NIVO/Ipi)\n*   **PD-L1 1-49%**\n    *   ICI + chemotherapy\n    *   ICI monotherapy\n    *   ICI combo therapy (NIVO/Ipi)\n*   **PD-L1 <1%**\n    *   ICI + chemotherapy\n    *   ICI combo therapy (NIVO/Ipi)\n\n---\n\n\n\n### ICI-chemotherapy options\n\n**Non-squamous**\n*   Carbo or Cis/Pemetrexed/Pembro\n*   Carbo/Taxol/Bev/Atezo\n*   Carbo/Nab-Paclitaxel/Atezo\n*   NIVO/Ipi + 2 cycles of histology-based chemotherapy\n\n**Squamous**\n*   Carboplatin/Taxane/Pembro\n*   NIVO/Ipi + 2 cycles of histology-based chemotherapy\n\n---\n\n<!-- Page 91 -->\n\nMale, 54y, Never smoker, No co-morbidities, ECOG PS 0\n\nPersistent cough with white phlegm\n\nCT: 3.5\\*3.9 cm lesions in lower lobe of right lung, multiple lymph node enlargement in mediastinum and hilum\n\nPET/CT: 3.6\\*3.9 cm tumor in lower right lung, involving the right diaphragm; multiple lymph node and bone metastasis Cranial MR: Enhanced small nodule in right parietal lobe, suspected enhanced small nodule in left parietal lobe.\n\nSpine MR: Multiple metastasis in vertebra, pelvis, and upper left femur.\n\nLung adenocarcinoma cT2N3M1, IV Stage (AJCC8th) EGFR/ALK/ROS1 PD-L1: TPS 80%\n\nNEXT OPTION ??\n\n---\n\n<!-- Page 92 -->\n\nDO NOT START IMMUNOTHERAPY Before checking for driver mutation on NGS even if the patient is positive for PDL1\n\nIF THE PATIENT IS POSITIVE FOR PDL1 and driver mutation – give weightage to driver mutation and start targeted therapy +/- chemo rather than PDL1\n\n---\n\n<!-- Page 93 -->\n\nKnown or suspected NSCLC\n\nContrast-Enhanced Chest CT (+liver & adrenal)\n*   Negative / borderline positive Chest CT, clinical stage I/II\n    *   FDG PET-CT\n        *   PET-CT(-) and peripheral cl\n            *   No further mediastinal work-up\n        *   PET-CT(-)\n            *   VATS or EBUS/EUS-NA\n        *   PET-CT(+)\n            *   Tissue confirmation required\n            *   Context-based strategy\n*   Massive N2/N3 disease on Chest CT\n    *   No further mediastinal work-up\n\n---\n\n<!-- Page 94 -->\n\nCT and PETCT OR PETCT\n*   **Mediastinal nodes Negative**\n    *   cNO and peripheral tumor ( outer 1/3rd ) Tsize - < 3 cms\n        *   SURGERY\n    *   N1 Or central tumor Tsize > 4 cms\n        *   Tissue confirmation EBUS / EUS Or VAM\n            *   Mediastinal nodes Negative\n                *   SURGERY\n            *   Mediastinal nodes POSITIVE\n                *   MULTIMODALITY TREATMNET\n*   **Mediastinal nodes Positive**\n    *   Tissue confirmation EBUS / EUS\n        *   Mediastinal nodes POSITIVE\n            *   MULTIMODALITY TREATMNET\n        *   Mediastinal nodes NEGATIVE\n            *   VAM\n                *   Mediastinal nodes POSITIVE\n                    *   MULTIMODALITY TREATMNET\n                *   Mediastinal nodes NEGATIVE\n                    *   SURGERY\n\n---\n\n<!-- Page 95 -->\n\nN2 disease\n*   **If Single station, Resectable:**\n    *   Neo-adjuvant Chemotherapy chemoradiation\n    *   Followed by Surgery\n*   **If Single station, unresectable:**\n    *   Definitive Chemoradiation & Durvalumab\n    *   If Residual Disease, then Surgery\n*   **If Multistation:**\n    *   Definitive Chemoradiation & Durvalumab\n    *   If Residual Disease, then Surgery\n*   **If Incidental:**\n    *   Adjuvant Chemotherapy\n\n---\n\n<!-- Page 96 -->\n\nWORK FLOW\n\nStage 4 lung carcinoma\n\nCheck biopsy report\nSquamous cell carcinoma or adeno ca\n\nIf squamous cell carcinoma –\n*   IHC for PDL1\n*   RTPCR FOR EGFR\n*   NGS – 12 gene / 52 gene / CGP (based on affordability)\n\nIf adeno ca –\n*   IHC for ALK, ROS, PDL1\n*   RT PCR FOR EGFR\n*   NGS – 12 gene / 52 gene / CGP (based on affordability)\n\nIf asymptomatic -\nWait for NGS or molecular reports and then start therapy based on report\n\nIf symptomatic – start chemo (pemetrexed + carboplatin for adenoca), gemcitabine + carboplatin (squamous cell ca)\n\nTrace molecular reports before cycle 2 and modify therapy based on reports\n\n---\n\n<!-- Page 97 -->\n\nThank you\n\nIn God I trust\nAll others require to show evidence\n\n---",
    "wordCount": 1247,
    "index": 15,
    "subTopicId": "1766794361883-ywzis95ke"
  }
]